Syncom Formulations (India) Ltd

Syncom Formul. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Syncom Formulations (India) Ltd

₹ 15.0 -3.78%
29 May - close price
syncomformulations.com BSE: 524470 NSE: SYNCOMF
About

Established in the year 1995, Syncom Formulations is a global pharmaceutical company that manufactures and markets a broad range of healthcare products. The company is a generic pharmaceutical player operating in more than 15 countries worldwide having more than 400 products registered.[1]

Key Points

Business Overview
The company manufactures and markets 500+ pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers. It is also involved in trading commodities and rental of properties. [1]

Website BSE NSE
  • Market Cap ₹ 1,411 Cr.
  • Current Price ₹ 15.0
  • High / Low ₹ 22.8 / 10.2
  • Stock P/E 18.6
  • Book Value ₹ 4.39
  • Dividend Yield 0.00 %
  • ROCE 26.8 %
  • ROE 20.2 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has delivered good profit growth of 21.2% CAGR over last 5 years

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • Earnings include an other income of Rs.31.0 Cr.
  • Working capital days have increased from 103 days to 164 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
61 59 62 63 73 87 101 127 148 117 121 115 134
55 53 56 57 64 76 90 112 131 101 103 93 113
Operating Profit 6 6 6 7 9 10 12 15 17 16 19 21 21
OPM % 10% 10% 10% 11% 12% 12% 12% 11% 12% 14% 15% 18% 16%
7 2 4 4 3 1 4 4 7 6 5 5 14
Interest 1 1 1 1 1 0 0 0 0 0 0 0 0
Depreciation 1 1 1 1 1 1 1 1 1 1 1 1 2
Profit before tax 10 6 8 9 9 10 15 17 23 20 22 25 33
Tax % 18% 27% 24% 25% 27% 24% 25% 24% 24% 22% 25% 25% 25%
8 4 6 6 7 8 11 13 18 16 17 19 25
EPS in Rs 0.09 0.05 0.07 0.07 0.07 0.08 0.12 0.14 0.19 0.17 0.18 0.20 0.26
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
173 184 185 159 187 206 245 216 222 257 461 487
155 167 168 147 175 189 207 196 202 229 407 409
Operating Profit 18 17 16 12 12 17 38 20 20 28 54 77
OPM % 11% 9% 9% 7% 6% 8% 16% 9% 9% 11% 12% 16%
1 3 3 4 5 5 7 12 15 13 17 31
Interest 0 0 0 0 0 1 0 2 3 5 1 1
Depreciation 3 3 3 4 4 4 4 4 5 5 5 7
Profit before tax 16 16 16 12 13 17 41 26 27 32 65 101
Tax % 38% 36% 33% 28% 12% 18% 28% 24% 24% 26% 24% 24%
10 10 11 9 11 14 29 20 20 24 49 76
EPS in Rs 0.13 0.13 0.14 0.11 0.14 0.18 0.37 0.23 0.21 0.25 0.52 0.81
Dividend Payout % 16% 15% 15% 0% 0% 0% 0% 13% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 10%
5 Years: 15%
3 Years: 30%
TTM: 6%
Compounded Profit Growth
10 Years: 22%
5 Years: 21%
3 Years: 56%
TTM: 57%
Stock Price CAGR
10 Years: 22%
5 Years: 14%
3 Years: 31%
1 Year: -32%
Return on Equity
10 Years: 13%
5 Years: 13%
3 Years: 15%
Last Year: 20%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 78 78 78 78 78 78 79 86 94 94 94 94
Reserves 22 31 36 44 55 68 109 136 162 192 246 318
6 6 12 12 9 2 62 58 83 72 4 1
31 61 48 37 32 33 42 28 38 33 66 116
Total Liabilities 138 175 175 171 173 181 292 308 377 392 410 529
46 46 85 89 89 93 91 94 91 120 125 184
CWIP 0 5 0 1 0 0 0 6 26 0 0 0
Investments 6 23 1 2 2 1 11 43 64 66 93 109
85 101 89 79 83 87 189 165 196 206 192 237
Total Assets 138 175 175 171 173 181 292 308 377 392 410 529

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
0 24 17 -2 4 6 -2 16 10 -6 23 58
1 -23 -8 -2 2 2 -75 -27 -45 84 -18 -51
1 -2 -2 -2 -0 -7 72 8 35 -15 -68 -3
Net Cash Flow 2 -1 6 -6 7 1 -5 -2 1 63 -63 4
Free Cash Flow -3 16 9 -8 10 4 -5 5 -10 -14 13 47
CFO/OP 32% 176% 128% 13% 66% 61% 24% 113% 86% 6% 70% 105%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 66 91 91 87 81 77 112 114 124 132 85 81
Inventory Days 34 43 29 37 37 39 51 51 53 49 49 81
Days Payable 63 130 92 75 57 49 66 36 52 33 51 96
Cash Conversion Cycle 37 4 27 49 61 67 96 129 124 148 83 66
Working Capital Days 84 40 45 75 74 88 28 33 -4 51 95 164
ROCE % 16% 15% 14% 9% 9% 12% 21% 11% 10% 10% 19% 27%

Insights

In beta
Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Total Permanent Employees
Number

Log in to view insights

Please log in to see hidden values.

Login
Number of SKUs (Pharmaceutical Formulations)
Number
Solar Power Generation
Lakh Units
Export Presence (Countries Served)
Count
Total Energy Consumed
Units

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
50.57% 50.57% 50.57% 50.57% 50.57% 50.57% 50.57% 50.57% 50.57% 50.57% 50.57% 50.57%
0.00% 0.00% 0.00% 0.08% 0.09% 0.10% 0.13% 0.11% 0.41% 0.10% 0.26% 0.21%
49.44% 49.44% 49.44% 49.35% 49.34% 49.34% 49.30% 49.32% 49.02% 49.33% 49.17% 49.23%
No. of Shareholders 2,24,9252,24,2522,89,9823,25,7613,76,5304,69,2424,89,5204,84,5294,71,0664,57,3644,42,2804,31,690

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Right Issue